Health Care · Services-Offices & Clinics of Doctors of Medicine

TDOC Teladoc Health, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 147744998 filings
Russell 2000

TDOC at a glance

Teladoc Health, Inc. (TDOC, SEC CIK 1477449) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 28, 2026 and Form 4 insider filings as recently as November 9, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Teladoc Health, Inc. (TDOC) reported revenue of $2.5 billion (down 1.5% from FY2024) and a net loss of $200.3 million. Diluted EPS was -$1.14.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Teladoc Health, Inc. (TDOC) shares worth $457.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Nueno Carlos on November 6, 2026 of 29,432 shares at $9.20 per share.
  • In the last 90 days, TDOC insiders reported 0 open-market purchases ($0) and 10 open-market sales ($732K) on Form 4, a net sale of $732K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.5B
−1.5% vs prior year
Insiders · 90 days
0 buys · 10 sells
Net −$732K
13F holders
30 funds
$457.6M · −2 vs prior quarter
Latest 8-K
Oct 28, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Global virtual care leader offering integrated healthcare services via technology platforms to employers, health plans, and individuals
  • New emphasis on AI-enhanced capabilities: Advanced AI-driven predictive analytics, personalized engagement, and AI-enabled clinical documentation improvements launched in Prism platform
  • Strategic shift to integrated mental health: Expanded mental health services fully embedded across longitudinal care programs and national rollout of insurance coverage acceptance for BetterHelp
  • Notable metric: Access for approximately 102 million U.S. members, with 17.1 million telehealth visits completed in 2025 across B2B and D2C channels
  • Unique fact: Established The Institute for Patient Safety and Quality of Virtual Care, first US-certified Patient Safety Organization dedicated to virtual care

Risk Factors

  • Regulatory risk: Impact of Patient Protection and Affordable Care Act (PPACA) and related laws reducing Medicare payments up to 2% annually through 2030
  • Geopolitical/macroeconomic threat: Revenue risk from potential Client mergers/acquisitions causing contract cancellations or non-renewals impacting 19% total revenue from top five Clients
  • Operational/supply chain vulnerability: Dependence on limited third-party suppliers for timely materials access risks supply chain disruptions and cost inflation
  • Competitive risk: Pricing pressure and market share loss from well-financed health plans and tech companies developing discounted competing virtual care services
  • Financial risk: Accumulated deficit $16.4B with net losses $200.3M in 2025 and $1B in 2024; reliance on raising capital on uncertain terms to fund operations

Management Discussion & Analysis

  • Revenue details for FY2025 vs FY2024 omitted; see 2024 10-K filed Feb 27, 2025 for full YoY analysis
  • U.S. Integrated Care members +9% YoY, increased by 8.0 million to 101.8 million as of Dec 31, 2025
  • Average monthly revenue per U.S. Integrated Care member down to $1.29 from $1.37 YoY, reflecting new member onboarding
  • BetterHelp paying users declined 5% YoY to 0.39 million for year ended Dec 31, 2025
  • $71.8 million goodwill impairments recorded in 2025 on Integrated Care acquisitions (Telecare, Catapult Health)
  • Goodwill balance $283.2 million as of Dec 31, 2025, all in BetterHelp segment; no impairment recorded on annual test
  • Amortization expense increased by $7.7 million in 2025 due to decreased useful life of trademarks; expects +$30.7 million in 2026
  • Risks from tariffs on imported components could impact operations; continued evaluation ongoing
  • Refunds on BetterHelp service $49.9 million in 2025 vs $84.0 million in 2024
  • Seasonality noted: Integrated Care strong in Q1 and Q4; BetterHelp reduces marketing spend in Q4 causing weaker operating income in Q1

AI summary of the TDOC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New litigation risk: derivative complaints consolidated in 2026, with Kimbrew filed September 17, 2026 alleging insider trading and misappropriation
  • Regulatory and compliance risk: BetterHelp privacy, advertising, contract, and tort lawsuits tied to the FTC’s July 2023 consent order
  • Competitive and market risk: BetterHelp revenue declined to $206.6 million from $236.9 million, while advertising fell to $98.8 million from $134.6 million
  • Financial risk: $1.0 billion of 1.25% convertible notes classified current, maturing June 1, 2027
  • Operational risk: chronic-condition brand transition increased amortization expense by $23.0 million through September 30, 2026

Management Discussion & Analysis

  • Q3 revenue $605.1M, down $21.3M or 3% YoY, driven by BetterHelp decline
  • Integrated Care best performer: revenue $398.5M, up 2%; Adjusted EBITDA margin 18.8% vs 17.0%
  • BetterHelp weakest segment: revenue $206.6M, down 13%; Adjusted EBITDA margin 2.2% vs 1.6%
  • Cash $849.9M; nine-month operating cash flow $180.6M vs $206.6M, free cash flow $85.4M
  • 2026 BetterHelp outlook reduced, with fewer users and lower revenue expected as cash-pay declines outpace insurance growth

AI summary of the TDOC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 revenue fell 3% to $605.1M, while adjusted EBITDA rose 14% to $79.4M, signaling margin-focused execution despite slower demand
  • Integrated Care grew 2% to $398.5M, with adjusted EBITDA margin improving to 18.8%, offsetting weakness elsewhere

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter 2026 financial results announced by Teladoc Health
  • Press release Exhibit 99.1 contains the detailed operating and financial results
Filed Sep 25, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Chief Legal Officer Adam C. Vandervoort resigns effective November 1, 2026, citing good reason under his severance agreement
  • Vandervoort to provide unpaid transition advisory services through November 1, 2027
Filed Aug 31, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Michael Grasher appointed CFO effective August 31, 2026, ending interim CFO arrangement while Charles Divita remains CEO
  • $550,000 annual salary, $500,000 sign-on bonus, and 85% target annual bonus beginning 2027

Item 7.01: Regulation FD Disclosure

  • Teladoc appointed Mr. Grasher as Chief Financial Officer
  • CFO transition may affect financial reporting, capital allocation and investor guidance

AI summaries of TDOC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for TDOC

Don't miss the next TDOC filing

  • Alerts as it files. A push when TDOC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut TDOC, by share count.
  • Ask anything. An AI agent that reads every TDOC filing and answers with sources.

TDOC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Nueno CarlosSellNov 6, 2026$9.20
Catapano Joseph RonaldSellOct 2, 2026$5.65
Catapano Joseph RonaldMOct 1, 2026-
Catapano Joseph RonaldMOct 1, 2026-
DIVITA CHARLES IIISellSep 11, 2026$6.10
DIVITA CHARLES IIIMSep 10, 2026-
DIVITA CHARLES IIIMSep 10, 2026-
DIVITA CHARLES IIIMSep 10, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$2.6B$2.6B$2.5B
Operating Income--$1.0B-$263.0M
Net Income-$220.4M-$1.0B-$200.3M
Op. Margin--39.7%-10.4%
Net Margin-8.5%-39.0%-7.9%
Balance Sheet
Total Assets-$3.5B$2.9B
Equity-$1.5B$1.4B
ROE--67.1%-14.5%
Per Share
EPS$-1.34$-5.87$-1.14
Cash Flow
Operating CF-$293.7M$294.4M
CapEx$11.5M$10.8M$8.9M

Source: XBRL data in Teladoc Health, Inc. (TDOC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate TDOC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
TDOC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$457.6M
Q2 202632$636.9M
Q1 202633$374.7M
Q4 202531$510.3M
Q3 202531$600.1M
Q2 202532$627.8M
Q1 202528$471.8M
Q4 202424$417.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 241 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

TDOC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 9, 2026--
10-QOct 29, 2026Analysis
8-KOct 28, 2026Analysis-
4Oct 5, 2026--
8-KSep 25, 2026Analysis-
4Sep 14, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 3, 2026--
4Sep 1, 2026--
8-KAug 31, 2026Analysis-
8-KAug 13, 2026Analysis-
4Aug 4, 2026--
8-KAug 3, 2026Analysis-
10-QJul 30, 2026Analysis
8-KJul 29, 2026Analysis-
4Jul 6, 2026--
4Jul 6, 2026--
4Jul 1, 2026--
4Jun 30, 2026--
SC 13GJun 22, 2026-
4Jun 12, 2026--

Related Health Care companies

All Health Care →

TDOC SEC filings: frequently asked questions

Are TDOC insiders buying or selling?

In the last 90 days, Teladoc Health, Inc. (TDOC) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $731,651 by 6 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold TDOC stock?

As of September 30, 2026, the largest Teladoc Health, Inc. (TDOC) holders among the 13F filers tracked by SignalX were BlackRock ($108.7 million), Vanguard Portfolio Management LLC ($82.7 million), Dimensional Fund Advisors ($52.8 million), Renaissance Technologies LLC ($46.4 million), Vanguard Capital Management LLC ($46.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was TDOC's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Teladoc Health, Inc. (TDOC) reported revenue of $2.5 billion (down 1.5% from FY2024) and a net loss of $200.3 million. Diluted EPS was -$1.14. The figures come from the XBRL data in the 10-K.

What are the main risks in TDOC's latest 10-K?

In the 10-K filed February 26, 2026, Teladoc Health, Inc. (TDOC) flagged: Regulatory risk: Impact of Patient Protection and Affordable Care Act (PPACA) and related laws reducing Medicare payments up to 2% annually through 2030. Geopolitical/macroeconomic threat: Revenue risk from potential Client mergers/acquisitions causing contract cancellations or non-renewals impacting 19% total revenue from top five Clients. (AI summary of the Risk Factors section.)

What did TDOC report in its latest 8-K?

Teladoc Health, Inc. (TDOC) filed an 8-K on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 revenue fell 3% to $605.1M, while adjusted EBITDA rose 14% to $79.4M, signaling margin-focused execution despite slower demand.

What are the latest TDOC SEC filings?

Teladoc Health, Inc. (TDOC) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on October 28, 2026 and a Form 4 insider filing on November 9, 2026.

What is TDOC's SEC CIK number?

Teladoc Health, Inc. (TDOC)'s SEC Central Index Key (CIK) is 1477449. EDGAR lists every TDOC filing under that number.

Ask anything about TDOC

The research agent reads TDOC's filings, financials, insider trades and 13F holders, then answers with sources.